Mutagenesis and Modeling of the Neurotensin Receptor NTR1

Catherine Labbé‐Jullié, Séverine Barroso, Delphine Nicolas-Etève, Jean-Louis Reversat, J. Botto, Jean Mazella, Jean‐Marie Bernassau, Patrick Kitabgi

Journal of Biological Chemistry · 1998 · 74 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

The two neurotensin receptor subtypes known to date, NTR1 and NTR2, belong to the family of G-protein-coupled receptors with seven putative transmembrane domains (TM). SR 48692, a nonpeptide neurotensin antagonist, is selective for the NTR1. In the present study we attempted, through mutagenesis and computer-assisted modeling, to identify residues in the rat NTR1 that are involved in antagonist binding and to provide a tentative molecular model of the SR 48692 binding site. The seven putative TMs of the NTR1 were defined by sequence comparison and alignment of bovine rhodopsin and G-protein-coupled receptors. Thirty-five amino acid residues within or flanking the TMs were mutated to alanine. Additional mutations were performed for basic residues. The wild type and mutant receptors were expressed in COS M6 cells and tested for their ability to bind125I-NT and [3H]SR 48692. A tridimensional model of the SR 48692 binding site was constructed using frog rhodopsin as a template. SR 48692 was docked into the receptor, taking into account the mutagenesis data for orienting the antagonist. The model shows that the antagonist binding pocket lies near the extracellular side of the transmembrane helices within the first two helical turns. The data identify one residue in TM 4, three in TM 6, and four in TM 7 that are involved in SR 48692 binding. Two of these residues, Arg327 in TM 6 and Tyr351 in TM 7, play a key role in antagonist/receptor interactions. The former appears to form an ionic link with the carboxylic group of SR 48692, as further supported by structure-activity studies using SR 48692 analogs. The data also show that the agonist and antagonist binding sites in the rNTR1 are different and help formulate hypotheses as to the structural basis for the selectivity of SR 48692 toward the NTR1 and NTR2. The two neurotensin receptor subtypes known to date, NTR1 and NTR2, belong to the family of G-protein-coupled receptors with seven putative transmembrane domains (TM). SR 48692, a nonpeptide neurotensin antagonist, is selective for the NTR1. In the present study we attempted, through mutagenesis and computer-assisted modeling, to identify residues in the rat NTR1 that are involved in antagonist binding and to provide a tentative molecular model of the SR 48692 binding site. The seven putative TMs of the NTR1 were defined by sequence comparison and alignment of bovine rhodopsin and G-protein-coupled receptors. Thirty-five amino acid residues within or flanking the TMs were mutated to alanine. Additional mutations were performed for basic residues. The wild type and mutant receptors were expressed in COS M6 cells and tested for their ability to bind125I-NT and [3H]SR 48692. A tridimensional model of the SR 48692 binding site was constructed using frog rhodopsin as a template. SR 48692 was docked into the receptor, taking into account the mutagenesis data for orienting the antagonist. The model shows that the antagonist binding pocket lies near the extracellular side of the transmembrane helices within the first two helical turns. The data identify one residue in TM 4, three in TM 6, and four in TM 7 that are involved in SR 48692 binding. Two of these residues, Arg327 in TM 6 and Tyr351 in TM 7, play a key role in antagonist/receptor interactions. The former appears to form an ionic link with the carboxylic group of SR 48692, as further supported by structure-activity studies using SR 48692 analogs. The data also show that the agonist and antagonist binding sites in the rNTR1 are different and help formulate hypotheses as to the structural basis for the selectivity of SR 48692 toward the NTR1 and NTR2. Many neuropeptide receptors belong to the family of GTP-binding protein-coupled receptors (GPCR) 1The abbreviations used are: GPCR, GTP-binding protein-coupled receptor; TM, transmembrane domain; NT, neurotensin; NTR1, neurotensin receptor 1; NTR2, neurotensin receptor 2; r, rat; m, mouse; h, human; IP, inositol phosphate. 1The abbreviations used are: GPCR, GTP-binding protein-coupled receptor; TM, transmembrane domain; NT, neurotensin; NTR1, neurotensin receptor 1; NTR2, neurotensin receptor 2; r, rat; m, mouse; h, human; IP, inositol phosphate.with seven putative transmembrane domains (TMs). The past decade has witnessed the discovery of a number of nonpeptide antagonist ligands of GPCRs for neuropeptides such as cholecystokinin, tachykinins, or angiotensin (1Woodruff G.N. Hughes J. Annu. Rev. Pharmacol. Toxicol. 1991; 31: 469-501Crossref PubMed Scopus (209) Google Scholar, 2Watling K.J. Krause J.E. Trends Pharmacol. Sci. 1993; 14: 81-84Abstract Full Text PDF PubMed Scopus (53) Google Scholar, 3Smith R.D. Chiu A.T. Wong P.C. Herblin W.F. Timmermans M.W.M. Annu. Rev. Pharmacol. Toxicol. 1992; 32: 135-165Crossref PubMed Scopus (249) Google Scholar). Most often, these compounds are selective for a given neuropeptide receptor subtype and, unlike peptides, cross the blood-brain barrier. As such, they have proven extremely useful for exploring the central and peripheral physiopathological functions associated with the receptor they antagonize. It seems to be a general feature that peptide agonist and nonpeptide antagonist bind to distinct epitopes of GPCRs. Site-directed mutagenesis of GPCRs, like vasopressin, tachykinins, or angiotensin receptors, has allowed for the determination of several conserved or specific residues that are involved in agonist and/or antagonist binding (4Mouillac B. Chini B. Balestre M.-N. Elands J. Trumpp-Kallmeyer S. Hoflack J. Hibert M. Jard S. Barberis C. J. Biol. Chem. 1995; 270: 25771-25777Abstract Full Text Full Text PDF PubMed Scopus (224) Google Scholar, 5Gether U. Johansen T.E. Snider R.M. Lowe III, J.A. Nakanishi S. Schwartz T.W. Nature. 1993; 362: 345-348Crossref PubMed Scopus (203) Google Scholar, 6Perlman S. Costa-Neto C.M. Miyakawa A.A. Schambye H.T. Hjorth S.A. Paiva A.C.M. Rivero R.A. Greenlee W.J. Schwartz T.W. Mol. Pharmacol. 1997; 51: 301-311Crossref PubMed Scopus (71) Google Scholar). In some studies, mutagenesis data were complemented by computer-assisted modeling to construct tridimensional models of ligand-receptor complexes (7Hibert M.F. Trumpp-Kallmeyer S. Hoflack J. Bruinvels A. Trends Pharmacol. Sci. 1993; 14: 7-12Abstract Full Text PDF PubMed Scopus (95) Google Scholar). This approach has led to the proposal of spatial models for the binding sites of a number of GPCRs that interact with small nonpeptide ligands (4Mouillac B. Chini B. Balestre M.-N. Elands J. Trumpp-Kallmeyer S. Hoflack J. Hibert M. Jard S. Barberis C. J. Biol. Chem. 1995; 270: 25771-25777Abstract Full Text Full Text PDF PubMed Scopus (224) Google Scholar, 8Trumpp-Kallmeyer S. Hoflack J. Bruinvels A. Hibert M. J. Med. Chem. 1992; 35: 3448-3462Crossref PubMed Scopus (424) Google Scholar, 9Befort K. Tabbara L. Kling D. Maigret B. Kieffer B.L. J. Biol. Chem. 1996; 271: 10161-10168Abstract Full Text Full Text PDF PubMed Scopus (152) Google Scholar). Multiplication of such tridimensional models of GPCRs, depicting the binding site for nonpeptide antagonists, would define a general binding epitope for these small nonpeptide ligands. This approach will be of great interest for the design of new selective high affinity molecules. The neuropeptide neurotensin (NT) exerts central actions that include hypothermia (10Bissette Nature. PubMed Scopus Google Sci. PubMed Scopus Google and a number of that the of and Biol. Google Scholar, 14: PubMed Scopus Google Scholar). Two receptors NTR1 and and have K. M. Nakanishi S. Full Text PDF PubMed Scopus Google Scholar, S. M. D. D. 1993; PubMed Scopus Google Scholar, M. M. J. B. D. 1996; PubMed Scopus Google Scholar, J. J. 1996; Google Scholar). and belong to the family of GPCRs. The NTR1 has high affinity for NT, the has affinity for the peptide and is by an receptor antagonist K. M. Nakanishi S. Full Text PDF PubMed Scopus Google Scholar, S. M. D. D. 1993; PubMed Scopus Google Scholar, M. M. J. B. D. 1996; PubMed Scopus Google Scholar, J. J. 1996; Google Scholar). receptors have central and peripheral and distinct S. M. D. D. 1993; PubMed Scopus Google Scholar, M. M. J. B. D. 1996; PubMed Scopus Google Scholar). SR 48692, a nonpeptide antagonist D. M. M. C. M. A. D. C. J. Sci. U. S. A. 1993; PubMed Scopus Google to the NTR1 M. M. J. B. D. 1996; PubMed Scopus Google Scholar, J. J. 1996; Google and has a useful to define the functions associated with receptor D. M. Pharmacol. 1995; PubMed Scopus Google Scholar). In SR 48692 of the to with M. M. C. D. Sci. 1997; PubMed Scopus Google Scholar). In the and to NT, that these are through the NTR1 J. Pharmacol. PubMed Scopus Google Scholar). data have that and SR 48692 bind to different of the NTR1 C. J. J. D. Mol. Pharmacol. 1995; Google Scholar). In the present study we attempted, through mutagenesis and computer-assisted modeling, to identify residues in the NTR1 that are involved in antagonist binding and to provide a tentative molecular model of the SR 48692 binding site. of the and of SR 48692 we to and residues present in or to the putative TMs of the NTR1 The wild type and mutant receptors were expressed in COS M6 cells and tested for their ability to bind125I-NT and [3H]SR 48692. A first tridimensional model of the SR 48692 binding site in the NTR1 was constructed using as a J. Mol. Biol. PubMed Scopus Google Scholar). SR 48692 was docked into the receptor, taking into account the mutagenesis data for orienting the antagonist in the transmembrane This model to a number of residues and that also interact with SR 48692 to construct and a of mutant of the in the seven transmembrane domains of and bovine rhodopsin The residues conserved the rNTR1 and the are by The TMs are in are that their extracellular side the of the residues are that were mutated in the present a GPCR, was the we these studies the with seven transmembrane tridimensional was known with some J. Mol. Biol. PubMed Scopus Google Scholar). structural data the of the transmembrane helices of the GPCR, has Nature. 1997; PubMed Scopus Google J. Mol. Biol. 1997; Scholar). the of the SR was by using rhodopsin of as a for modeling the NTR1 and by SR 48692 into the of the seven helices as to the mutagenesis model a number of residues in TMs 6 and 7 that are involved in SR 48692 binding. Two of these residues, Arg327 in TM 6 and Tyr351 in TM 7, play a key role in antagonist/receptor interactions. The data also show that the agonist and antagonist binding sites in the rNTR1 are they help formulate hypotheses as to the structural basis for the selectivity of SR 48692 toward the NTR1 and NTR2. was and SR 48692, SR and SR was as in C. D. J. J. J. 1993; PubMed Scopus Google [3H]SR 48692 was The rNTR1 is a of Nakanishi K. M. Nakanishi S. Full Text PDF PubMed Scopus Google Scholar). The to the the was used as a for mutagenesis as J. D. M. A. J. Mol. 1997; PubMed Scopus Google Scholar). were by of the mutant receptors were by the were into and were COS M6 cells were in bovine and with cells the were with and for with of in the of in with cells were with and for cells were with in by through a and for were in of and was by the with the wild type rNTR1 or the receptor, cells were and for in in in the of of two with bovine cells were for in of in with or of was the in of for The was by of the was and by of were by with of and of and The in the was of of for the two were with of in a of of bovine and for The was by of of and by two of the and with of the binding was in the of of to for or to for [3H]SR 48692 were of ligands were with and data were by the D. PubMed Scopus Google Scholar). binding data with by for a given receptor different they to binding and to for [3H]SR 48692 binding the wild type and mutant receptors. a given receptor, the for the antagonist was two to that for the This is to the in the binding sites that are in a high affinity as C. J. J. D. Mol. Pharmacol. 1995; Google Scholar). The rNTR1 sequence was by of the J. M. and B. with of the the and GPCRs, and bovine rhodopsin J. Mol. Biol. 1997; to define by sequence comparison the in the rNTR1 that would to the seven putative TMs to in such receptors. domains are in A model of the TMs of the rNTR1 was using the by rhodopsin residue side by the one in the rNTR1 a was by the with a of and with and the helical and 6 residues within TMs or near the the TMs and the extracellular domains of the rNTR1 were mutated into and The wild type and mutant receptors were expressed in COS M6 and with or [3H]SR 48692 were performed with for ligands are in of the rNTR1 in TMs 4, and the affinity of In mutations and in TM 6, and and in TM 7, receptors that [3H]SR 48692 binding. In the in TM 7 a in antagonist mutations the affinity of and or in a in affinity the in TM 7 led to an of agonist binding in antagonist affinity and for neurotensin and SR 48692 binding to wild type and mutated in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to M6 cells were with wild type and mutated and used for binding as in were of binding or [3H]SR 48692 as in were binding with and SR 48692 as the and as the The are the of three to in a new COS M6 cells were with wild type and mutated and used for binding as in were of binding or [3H]SR 48692 as the in antagonist binding affinity for mutant receptors that bind [3H]SR 48692, with SR 48692 and were performed using as the were for and are in The the and and the mutant and in for SR 48692, as with the wild type The data also the antagonist affinity of the mutant and the agonist affinity of the and in model of the rNTR1 was constructed using as a template. SR 48692 was docked into the taking into account the mutagenesis of the SR that a number of residues interact with the antagonist. In that the carboxylic of the antagonist form an ionic link with one of four basic residues in the in TM TM Arg327 and in TM The model also that and/or in TM interact with the of SR 48692 and that one or several or residues TM in TM and in TM in and and in TM the the mutant receptors were constructed and tested in binding and The the binding affinity of SR 48692 or In the mutant a for the antagonist and a and for NT, as with the wild type rNTR1 The mutant a in SR 48692 affinity and in The and SR 48692 and with the affinity as the wild type and for neurotensin and SR 48692 binding to wild type and mutated in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to in were binding with and SR 48692 as the and as the The are the of three to M6 cells were with wild type and mutated and used for binding as in were of binding or [3H]SR 48692 as in were binding with and SR 48692 as the and as the The are the of three to in a new COS M6 cells were with wild type and mutated and used for binding as in were of binding or [3H]SR 48692 as to or to or and to the affinity of the rNTR1 for SR 48692 or In the and were of antagonist and agonist binding The that Arg327 is for antagonist and agonist binding or that the mutated receptors were expressed in COS M6 these two was in COS M6 cells the wild type rNTR1 or the A shows that and were in the of was by with the mutant as with the wild type rNTR1 SR 48692 the in was by with the mutant as with the wild type receptor that in wild type cells was in with for binding to receptor of SR 48692 and for in wild type COS M6 48692, M6 cells were with the wild type rNTR1 and the mutant and was as for are for the were their as 4, by the and Pharmacol. PubMed Scopus Google Scholar, Trends Pharmacol. Sci. 1993; 14: Full Text PDF PubMed Scopus Google in the of agonist used in the and the of were and with the wild type and the mutant receptor, The are the of three to in a new COS M6 cells were with the wild type rNTR1 and the mutant and was as for are for the were their as 4, by the and Pharmacol. PubMed Scopus Google Scholar, Trends Pharmacol. Sci. 1993; 14: Full Text PDF PubMed Scopus Google in the of agonist used in the and the of were and with the wild type and the mutant receptor, The are the of three to The in of SR 48692 with the mutant receptor is with the side of an ionic link with the carboxylic of the antagonist. two SR 48692 SR and SR were tested for their ability to in COS M6 with the wild type rNTR1 or the mutant SR and SR are to SR 48692 for the is by a the that the carboxylic studies have that SR and SR bind with and affinity SR 48692 to the C. J. J. D. Mol. Pharmacol. 1995; Google Scholar). studies have that the spatial of the in SR 48692 and SR is SR two by the carboxylic in L. D. J. Chem. 1996; Scopus Google Scholar). we that the the of SR that of SR with the The in and are with in wild type COS M6 cells with that their binding affinity C. J. J. D. Mol. Pharmacol. 1995; Google Scholar). In cells the the of SR to was by a that of SR was A model of the rNTR1 was constructed using the tridimensional of rhodopsin as a Nature. 1997; PubMed Scopus Google Scholar, J. Mol. Biol. 1997; Scholar). SR 48692 was docked into the receptor, taking into account the mutagenesis data of the SR is in The antagonist binding pocket is in the of the transmembrane with the group of SR 48692 the of the and the of the two helical the of the Most of the residues as to the binding of SR 48692 are within TMs 6 and into account the in antagonist affinity by these residues, the antagonist and the receptor be as the of the antagonist is toward the extracellular side of the and with the side of and the carboxylic of SR 48692 an ionic with the group of Arg327 in the group with the in the of the and with and the toward the side of the and with the side of Tyr351 to a one of and a the group and and and and/or with the side of and In the present we have of two in an to the molecular the of SR 48692, a nonpeptide antagonist, with the The first approach computer-assisted modeling of the rNTR1 to a that has for a number of GPCRs (7Hibert M.F. Trumpp-Kallmeyer S. Hoflack J. Bruinvels A. Trends Pharmacol. Sci. 1993; 14: 7-12Abstract Full Text PDF PubMed Scopus (95) Google Scholar). in the in to GPCRs the known tridimensional of J. Mol. Biol. PubMed Scopus Google Scholar). has a with seven transmembrane is a the tridimensional helical of a GPCR, was Nature. 1997; PubMed Scopus Google Scholar, J. Mol. Biol. 1997; Scholar). used rhodopsin as a in model of the The approach involved mutagenesis of the rNTR1 to residues that interact with SR 48692. This the antagonist into the receptor, led to the model in for the It be that model was constructed the that the residues for SR 48692 are involved in molecular with the antagonist. is that is for the data to the are of these will be further the residues as to the binding of the antagonist, were within TMs 6 and 7 or the these TMs and the extracellular This appears to be a feature of peptide receptors with to nonpeptide antagonist binding. studies have that nonpeptide of the and angiotensin receptors bind to epitopes that are within and/or the extracellular and transmembrane helices U. Johansen T.E. Snider R.M. Lowe III, J.A. Nakanishi S. Schwartz T.W. Nature. 1993; 362: 345-348Crossref PubMed Scopus (203) Google Scholar, D. J. Biol. Chem. Full Text PDF PubMed Google Scholar, U. Lowe III, J.A. Snider R.M. Nakanishi S. Schwartz T.W. Sci. U. S. A. 1993; PubMed Scopus Google Scholar, M. Nature. 1993; 362: PubMed Scopus Google Scholar, M. K.J. K. J. Biol. Chem. Full Text PDF PubMed Google Scholar, H.T. Hjorth S.A. Schwartz T.W. Sci. U. S. A. PubMed Scopus Google Scholar). TMs 6 and 7 are involved in the binding of the small nonpeptide ligands U. Johansen T.E. Snider R.M. Lowe III, J.A. Nakanishi S. Schwartz T.W. Nature. 1993; 362: 345-348Crossref PubMed Scopus (203) Google D. J. Biol. Chem. Full Text PDF PubMed Google Scholar, U. Lowe III, J.A. Snider R.M. Nakanishi S. Schwartz T.W. Sci. U. S. A. 1993; PubMed Scopus Google Scholar, M. Nature. 1993; 362: PubMed Scopus Google Scholar, M. K.J. K. J. Biol. Chem. Full Text PDF PubMed Google Scholar, H.T. Hjorth S.A. Schwartz T.W. Sci. U. S. A. PubMed Scopus Google Scholar). feature of peptide GPCRs lies in the different binding epitopes for peptide and nonpeptide This has for the and receptors (4Mouillac B. Chini B. Balestre M.-N. Elands J. Trumpp-Kallmeyer S. Hoflack J. Hibert M. Jard S. Barberis C. J. Biol. Chem. 1995; 270: 25771-25777Abstract Full Text Full Text PDF PubMed Scopus (224) Google Scholar, 5Gether U. Johansen T.E. Snider R.M. Lowe III, J.A. Nakanishi S. Schwartz T.W. Nature. 1993; 362: 345-348Crossref PubMed Scopus (203) Google Scholar, D. J. Biol. Chem. Full Text PDF PubMed Google Scholar, U. Lowe III, J.A. Snider R.M. Nakanishi S. Schwartz T.W. Sci. U. S. A. 1993; PubMed Scopus Google Scholar, M. Nature. 1993; 362: PubMed Scopus Google Scholar, M. K.J. K. J. Biol. Chem. Full Text PDF PubMed Google Scholar, H.T. Hjorth S.A. Schwartz T.W. Sci. U. S. A. PubMed Scopus Google Scholar, A. C. Nature. 1993; 362: PubMed Scopus Google Scholar, D. J. Biol. Chem. Full Text PDF PubMed Google Scholar). present data with a number of mutations that SR 48692 binding and or binding. in an of agonist binding antagonist binding. have that a of the of the rNTR1 also binding affinity SR 48692 affinity C. J. J. D. Mol. Pharmacol. 1995; Google Scholar). these data that SR 48692 and bind to distinct epitopes the the mutant receptors, Arg327 that affinity for SR 48692 high affinity binding to This that the mutant receptors were expressed the of COS M6 cells and that the mutations the of the Two residues, Tyr351 and were to play a key role in SR 48692 binding. The mutant a in affinity for the antagonist and a in agonist lies to Tyr351 in the extracellular the in binding with [3H]SR 48692, of This shows that the two residues in spatial that are for and antagonist and agonist binding. data that the SR 48692 affinity for the mutant a of Tyr351 with the antagonist a of the receptor a in in the of Tyr351 be to the side of the is for binding and, to agonist The in SR 48692 affinity of the mutant receptor is with the and of Tyr351 with the and of the antagonist. studies using SR 48692 structural of these useful to the role of antagonist binding. The mutant receptor was of SR 48692 and binding. expressed in COS M6 the ability to to by an the of was by of with the mutant as with the wild type receptor, the was for receptors, that they were expressed we have with the wild type rNTR1 that is to the of In shows that the mutant is to and and, that was by the SR 48692 with a in COS M6 cells with the mutant as with the wild type a in is with an ionic link with the carboxylic of the antagonist, as in This proposal is further supported by the with the SR and SR in the of the group by the as by studies L. D. J. Chem. 1996; Scopus Google Scholar). The is for SR 48692 and the SR in in the SR C. J. J. D. Mol. Pharmacol. 1995; Google Scholar, L. D. J. Chem. 1996; Scopus Google Scholar). The that the of SR was by the in to that of SR 48692 and SR in of the of an ionic link the carboxylic of the antagonist. data also to a role of Arg327 in the binding site. It is that Arg327 an ionic with the group of NT, as has to be for binding J.E. J. Biol. Chem. Full Text PDF PubMed Google Scholar). are in to In a the binding site of in the rNTR1 was to in the extracellular computer-assisted modeling of the receptor and the peptide B. K. J. Biol. Chem. 1996; 271: Full Text Full Text PDF PubMed Scopus Google Scholar). NTR1 the extracellular and the and as involved in toward B. K. J. Biol. Chem. 1996; 271: Full Text Full Text PDF PubMed Scopus Google Scholar). It is that and also of the residues that are for SR 48692 binding. This that the binding sites of and SR 48692 in the rNTR1 are to and the that SR 48692 as an antagonist of binding and D. M. M. C. M. A. D. C. J. Sci. U. S. A. 1993; PubMed Scopus Google Scholar). a receptor subtype was rat and M. M. J. B. D. 1996; PubMed Scopus Google Scholar, J. J. 1996; Google Scholar). This receptor to the family of GPCRs and with the The functions associated with receptor are as SR 48692 with and affinity to the and to the rNTR1 M. M. J. B. D. 1996; PubMed Scopus Google Scholar, J. J. 1996; Google Scholar). SR 48692 shows selectivity for the NTR1. the residues that were in the present study to play a role in SR 48692 binding to the rNTR1 are conserved in the and is by a residue in The in the rNTR1 in a in SR 48692 In with the of the antagonist. It is that an group to the of these and in for antagonist This be tested by the in the rNTR1 or the in the In residues to be to the affinity and selectivity of SR 48692 for the NTR1. The present model be to further mutagenesis studies of the NTR1 and and to new with high selectivity for of these receptors. This in help in their to the of are to and for the of

References

35